As anti-CD30 CAR T-cells expressing CCR4 lead to improved tumor honing and anti-lymphoma activity when compared with anti-CD30 CAR T-cells lacking CCR4 [101], this approach is now being studied in a clinical trial of patients with R/R CD30+ cHL and CTCL. Here, CCR4 is linked to neoplasm.